Advantage Investment Management’s Abiomed Inc ABMD Stock Holding History

Advantage Investment Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$135K	Sell	758 -236	-24%	-$51K	0.11%	187
2019 Q2	$259K	Buy	994 +8	+0.8%	+$2.12K	0.2%	117
2019 Q1	$282K	Hold	986	–	–	0.22%	88
2018 Q4	$320K	Hold	986	–	–	0.24%	74
2018 Q3	$443K	Buy	986 +46	+5%	+$18.1K	0.29%	70
2018 Q2	$385K	Hold	940	–	–	0.28%	71
2018 Q1	$274K	Hold	940	–	–	0.1%	136
2017 Q4	$176K	Hold	940	–	–	0.05%	196
2017 Q3	$158K	Sell	940 -390	-29%	-$59K	0.05%	192
2017 Q2	$191K	Hold	1,330	–	–	0.07%	166
2017 Q1	$167K	Hold	1,330	–	–	0.07%	160
2016 Q4	$150K	Sell	1,330 -507	-28%	-$58.7K	0.06%	171
2016 Q3	$236K	Sell	1,837 -108	-6%	-$12.9K	0.09%	127
2016 Q2	$213K	Buy	1,945 +41	+2%	+$4.08K	0.1%	124
2016 Q1	$181K	Buy	1,904 +117	+7%	+$9.88K	0.08%	142
2015 Q4	$161K	Hold	1,787	–	–	0.08%	155
2015 Q3	$166K	Hold	1,787	–	–	0.09%	139
2015 Q2	$117K	Hold	1,787	–	–	0.06%	214
2015 Q1	$128K	Buy	+1,787	New	+$97K	0.07%	190

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Advantage Investment Management's ABMD Position: Q3 2019 in Review

Advantage Investment Management reduced its Abiomed Inc (ABMD) stake by 24% in Q3 2019, selling an estimated $51K and leaving 758 shares worth $135K. The position accounts for 0.11% of the portfolio, ranked #187.

Advantage Investment Management first reported a position in ABMD in Q1 2015 and has held it in 19 quarters since. The position peaked at $443K in Q3 2018. 443 funds tracked by Wall St. Rank hold ABMD as of Q3 2019.

Advantage Investment Management held 758 shares of Abiomed Inc worth $135K as of Q3 2019.
Advantage Investment Management sold 236 Abiomed Inc shares in Q3 2019, an estimated $51K.
Abiomed Inc made up 0.11% of Advantage Investment Management's portfolio in Q3 2019, its #187 holding.
Advantage Investment Management first reported a position in Abiomed Inc in Q1 2015 and has held it in 19 quarters since.
Advantage Investment Management's Abiomed Inc position peaked at $443K in Q3 2018.
443 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.